Syqe Medical’s Selective-Dose inhaler aims to increase the effectiveness of patient treatment by delivering a range of drugs in breakthrough precision levels. This new level of precision allows patients to reach the coveted optimum balance between symptom relief and adverse events, and regain their quality of life.
Finding a need to build a high-precision, high-temperature and electrically insulated test facility for product development, Syqe Medical first looked to PEEK materials and traditional manufacturing methods because of the heat resistance requirements. However, according to Syqe Medical Founder and CEO Perry Davidson, design processes were constrained, requiring many adjustments and consequently, production costs were high, delivery times long and yet still the materials were not durable enough.